influenza
viru
rna
orthomyxoviru
approxim
kb
length
eightseg
genom
typic
classifi
basi
hemagglutinin
ha
neuraminidas
na
main
variant
respect
genet
reassort
underpin
potenti
transmiss
differ
host
speci
evolut
highli
pathogen
variant
recogn
list
ten
threat
global
health
season
influenza
caus
estim
death
global
year
variant
alon
kill
peopl
year
unit
state
certain
group
particularli
risk
includ
older
adult
infant
young
children
pregnant
women
underli
lung
diseas
immunocompromis
burden
diseas
disproportion
affect
lowmiddleincom
set
influenza
viru
diagnost
surveil
fundament
identifi
emerg
novel
strain
improv
predict
potenti
epidem
pandem
inform
vaccin
strategi
diagnost
data
facilit
realtim
surveil
underpin
infect
control
intervent
inform
prescript
neuraminidas
inhibitor
nai
current
clinic
diagnost
test
influenza
viru
depend
detect
viral
antigen
pcr
amplif
viral
nucleic
acid
deriv
respiratori
sampl
two
approach
offer
tradeoff
benefit
follow
antigen
test
includ
pointofcar
test
poct
typic
rapid
low
sensit
pcr
timeconsum
sensit
irrespect
test
use
clinic
diagnost
facil
report
nonquantit
binari
diagnost
result
data
routin
gener
influenza
diagnosi
limit
capac
inform
insight
epidemiolog
linkag
vaccin
efficaci
antivir
suscept
ground
aspir
gener
new
diagnost
test
combin
speed
incorpor
potenti
poct
sensit
detect
coinfect
gener
quantit
semiquantit
data
use
identifi
drug
resist
reconstruct
phylogeni
inform
surveil
public
health
strategi
vaccin
design
applic
oxford
nanopor
technolog
ont
sequenc
gener
fulllength
influenza
viru
sequenc
clinic
respiratori
sampl
address
challeng
ont
offer
thirdgener
portabl
realtim
approach
gener
longread
singlemolecul
sequenc
data
demonstr
success
across
rang
virus
date
nanopor
sequenc
influenza
viru
report
use
hightit
viru
vitro
cultur
system
produc
fulllength
genom
sequenc
direct
rna
sequenc
use
target
enrich
either
hybrid
cdna
influenza
virusspecif
pcr
amplif
therefor
aim
optim
metagenom
protocol
detect
influenza
virus
directli
clinic
sampl
use
nanopor
sequenc
determin
sensit
compar
exist
diagnost
method
accuraci
compar
shortread
illumina
sequenc
use
clinic
sampl
hospit
patient
influenza
season
sampl
control
laboratori
infect
ferret
optim
requir
nanopor
method
roll
diagnost
test
highlight
potenti
impact
technolog
advanc
molecular
diagnost
respiratori
pathogen
collect
respiratori
sampl
clinic
microbiolog
laboratori
oxford
univers
hospit
nh
foundat
trust
larg
tertiari
referr
teach
hospit
southeast
england
work
anonym
residu
materi
throat
nose
swab
gener
result
routin
clinic
investig
januari
may
sampl
collect
use
steril
polyest
swab
inocul
ml
steril
viral
transport
medium
vtm
use
standard
approach
describ
cdc
websit
studi
respiratori
sampl
submit
clinic
diagnost
laboratori
routin
test
pcrbase
test
use
genexpert
assay
cepheid
detect
influenza
b
virus
respiratori
syncyti
viru
rsv
workflow
shown
fig
sampl
patient
design
highrisk
locat
hematolog
oncolog
critic
care
test
use
biofir
filmarray
detect
expand
panel
bacteri
viral
pathogen
quantit
data
cycl
threshold
ct
gener
genexpert
assay
use
influenza
viru
ct
valu
estim
viral
titer
clinic
sampl
use
genexpert
assay
pcr
cycl
perform
sampl
call
neg
ie
posit
ct
valu
quantif
avail
biofir
result
methodolog
assess
focus
four
categori
sampl
follow
posit
pool
neg
pool
individu
posit
sampl
individu
neg
sampl
posit
pool
pool
throat
swab
sampl
test
posit
influenza
viru
clinic
diagnost
laboratori
provid
larg
enough
sampl
assess
reproduc
fig
neg
pool
gener
three
pool
throat
swab
sampl
test
neg
influenza
viru
consist
individu
sampl
fig
individu
posit
sampl
includ
individu
sampl
throat
swab
nasal
swab
test
posit
influenza
b
viru
select
repres
widest
rang
genexpert
assay
ct
valu
valid
test
result
rang
individu
neg
sampl
select
individu
throat
swab
sampl
influenza
viru
neg
quantifi
viral
titer
hazara
viru
stock
pool
influenza
virusposit
throat
swab
quantit
revers
transcriptionpcr
qrtpcr
use
previous
describ
assay
standard
prior
establish
protocol
detail
full
assess
impact
two
possibl
optim
step
centrifug
versu
filtrat
reduc
time
cdna
synthesi
centrifug
versu
filtrat
investig
two
approach
deplet
humanbacteri
nucleic
acid
sampl
ie
filtrat
raw
sampl
via
filter
sartoriu
process
versu
use
hard
spin
g
min
cdna
librari
comparison
produc
describ
previous
reduc
time
cdna
synthesi
assess
possibl
time
save
cdna
synthesi
step
compar
perform
previous
describ
protocol
modifi
version
two
alter
first
use
superscript
iv
thermo
fisher
place
superscript
iii
thermo
fisher
revers
transcript
incub
time
reduc
min
min
second
reduc
cdna
amplif
pcr
extens
cycl
time
min
min
prior
nucleic
acid
extract
sampl
spike
hazara
viru
virion
final
concentr
genom
copi
per
ml
posit
intern
control
envelop
negativestrand
rna
viru
genu
orthonairoviru
order
bunyaviral
triseg
genom
nucleotid
length
genbank
access
number
nonpathogen
human
would
therefor
anticip
aris
clinic
sampl
cultur
virion
cell
line
provid
nation
collect
pathogen
virus
ncpv
catalog
sampl
centrifug
g
min
supernat
elut
without
disturb
pellet
materi
use
nucleic
acid
extract
total
nucleic
acid
extract
supernat
use
qiaamp
viral
rna
kit
qiagen
elut
follow
dnase
treatment
turbo
dnase
thermo
fisher
scientif
min
rna
purifi
concentr
use
rna
clean
kit
zymo
research
follow
manufactur
instruct
randomli
amplifi
cdna
prepar
sampl
use
sequenceindepend
singleprim
amplif
sispa
approach
adapt
previous
describ
workflow
base
round
ab
methodolog
revers
transcript
rna
primer
mix
incub
min
cool
room
temperatur
firststrand
synthesi
perform
addit
superscript
iv
firststrand
buffer
mm
dinucleosid
triphosph
dntp
dithiothreitol
dtt
superscript
iv
thermo
fisher
incub
min
secondstrand
synthesi
perform
addit
sequenas
buffer
sequenas
affymetrix
prior
incub
min
follow
addit
sequenas
dilut
buffer
sequenas
incub
min
amplif
cdna
perform
triplic
use
reaction
mixtur
input
accutaq
la
sigma
reaction
mixtur
accord
manufactur
instruct
use
primer
b
pcr
cycl
condit
cycl
min
follow
min
amplifi
cdna
pool
triplic
reaction
mixtur
purifi
use
ratio
ampur
xp
bead
beckman
coulter
brea
ca
quantifi
use
qubit
highsensit
doublestrand
dna
dsdna
kit
thermo
fisher
accord
manufactur
instruct
multiplex
sequenc
librari
prepar
use
ng
cdna
sampl
input
kit
barcod
individu
use
nativ
barcod
oxford
nanopor
technolog
modifi
onepot
protocol
http
librari
sequenc
flow
cell
minion
gridion
devic
oxford
nanopor
technolog
sequenc
proceed
h
sampl
batch
accord
genexpert
ct
valu
see
file
supplement
materi
nextera
xt
kit
illumina
sequenc
librari
prepar
use
ng
amplifi
cdna
per
manufactur
instruct
sequenc
pairedend
illumina
miseq
run
genom
servic
develop
unit
public
health
england
nanopor
read
base
call
use
guppi
oxford
nanopor
technolog
oxford
uk
output
base
call
fastq
file
demultiplex
use
porechop
http
githubcomrrwickporechop
read
first
taxonom
classifi
refseq
databas
use
centrifug
read
map
refer
sequenc
select
centrifug
report
use
draft
consensu
sequenc
gener
use
major
vote
approach
determin
nucleotid
posit
result
draft
consensu
sequenc
subject
blast
search
influenza
viru
sequenc
databas
includ
season
influenza
viru
sequenc
download
influenza
research
databas
read
map
refer
sequenc
use
number
map
read
calcul
use
samtool
pysam
http
githubcompysamdeveloperspysam
subtyp
influenza
viru
deriv
clinic
sampl
determin
subtyp
ha
na
refer
sequenc
consensu
sequenc
built
use
nanopolish
marginconspi
script
http
githubcomzibraprojectzikapipelin
illumina
data
read
qualiti
trim
minimum
score
across
read
trimmomat
bwamem
use
align
read
refer
genom
use
mem
default
samtool
use
comput
percent
read
map
coverag
depth
map
consensus
illumina
sequenc
gener
use
quasibam
maximum
likelihood
phylogeni
gener
ha
gene
segment
use
raxml
gener
timerevers
model
nucleotid
substitut
gammadistribut
rate
variat
among
site
appli
sequenc
align
perform
use
muscl
appli
sequenc
approach
residu
sampl
collect
previou
time
cours
experi
undertaken
control
laboratori
environ
test
ferret
nasal
salin
wash
sampl
three
independ
anim
time
cours
day
prior
first
exposur
influenza
viru
day
postinfect
sampl
plaqu
assay
viral
titer
describ
previous
studi
anonym
discard
clinic
sampl
approv
londonqueen
squar
research
ethic
committe
ferret
sampl
residu
sampl
exist
studi
project
licens
review
local
anim
welfar
ethic
review
board
public
health
england
porton
subsequ
grant
home
offic
follow
remov
human
read
sequenc
data
upload
european
bioinformat
institut
http
wwwebiacuk
bioproject
number
method
protocol
shown
fig
first
sequenc
five
influenza
virusposit
five
influenza
virusneg
throat
swab
spike
hazara
viru
control
genom
copiesml
use
sequenceindepend
singleprim
amplif
sispa
approach
follow
nanopor
sequenc
produc
metagenom
data
domin
read
bacteri
origin
extrem
viral
read
detect
pass
sampl
filter
prior
nucleic
acid
extract
increas
detect
viral
read
sever
order
magnitud
fig
filtrat
rel
expens
also
assess
altern
approach
ad
rapidcentrifug
step
pellet
bacteri
human
cell
follow
nucleic
acid
extract
supernat
use
pool
set
influenza
virusposit
sampl
concentr
genom
copiesml
provid
larg
enough
sampl
assess
reproduc
hazara
viru
control
spike
genom
copiesml
enrich
influenza
viru
hazara
viru
similar
filtrat
versu
centrifug
base
read
map
viral
genom
fig
centrifug
simpler
less
expens
select
approach
test
synthesi
tag
randomli
prime
cdna
subsequ
amplif
via
sispa
requir
lengthi
revers
transcript
pcr
step
h
h
min
respect
optim
stage
upgrad
revers
transcriptas
superscript
iii
superscript
iv
thermo
fisher
reduc
incub
time
min
process
time
reduct
min
reduc
pcr
extens
time
within
cycl
min
min
h
min
process
time
reduct
compar
final
method
origin
protocol
use
triplic
extract
pool
set
influenza
virusposit
sampl
demonstr
signific
loss
perform
rapid
protocol
fig
adopt
approach
routin
protocol
give
wetlab
process
time
h
start
influenza
virusposit
sampl
pool
genom
copiesml
made
three
volumetr
dilut
seri
use
three
independ
influenza
virusneg
pool
fig
total
quantiti
cdna
prepar
sequenc
consist
higher
sampl
use
neg
pool
diluent
fig
indic
presenc
higher
concentr
nonvir
rna
within
pool
like
due
host
cell
lysi
higher
bacteri
presenc
demonstr
variabl
natur
throat
swab
sampl
consist
retriev
hazara
viru
read
three
dilut
seri
nanopor
sequenc
independ
influenza
viru
titer
sampl
fig
sequenc
dilut
seri
gave
consist
proport
total
read
map
hazara
viru
genom
across
dilut
first
two
pool
mean
standard
deviat
valu
per
pool
read
per
million
rpm
total
read
rpm
respect
pool
dilut
seri
gener
rpm
hazara
viru
read
across
sampl
show
decreas
trend
associ
increas
dilut
factor
increasingli
nonvir
rna
introduc
highbackground
pool
nanopor
sequenc
triplic
sispa
prepar
influenza
virusposit
pool
produc
mean
standard
deviat
rpm
map
influenza
viru
genom
fig
across
dilut
seri
proport
influenza
viru
read
strongli
associ
influenza
viru
titer
p
valu
also
influenc
neg
pool
use
dilut
consist
pattern
observ
hazara
viru
control
sequenc
neg
control
pool
influenza
viru
spike
gener
read
map
influenza
viru
influenza
viru
titer
copiesml
influenza
viru
read
inconsist
detect
across
sampl
fig
suggest
limit
detect
influenza
viru
copiesml
hazara
viru
control
genom
copiesml
spike
genom
coverag
depth
pool
coverag
highbackground
pool
vari
fig
influenza
viru
genom
coverag
copiesml
segment
sampl
fig
genom
copiesml
influenza
viru
mean
coverag
per
segment
pool
substanti
reduc
highbackground
pool
fig
influenza
viru
titer
copiesml
coverag
highli
vari
across
genom
segment
howev
present
copiesml
pool
suffici
data
correct
subtyp
tabl
demonstr
abil
retriev
influenza
viru
sequenc
pool
influenza
virusposit
materi
dilut
neg
sampl
next
appli
method
individu
anonym
clinic
sampl
sampl
test
influenza
viru
posit
sampl
test
influenza
viru
neg
clinic
diagnost
laboratori
data
yield
vari
flow
cell
rang
read
multiplex
sampl
within
flow
cell
barcod
perform
inconsist
use
stringent
dualbarcod
demultiplex
method
clinic
sampl
rang
total
read
gener
median
read
tabl
read
map
either
influenza
b
viru
genom
present
sampl
ct
rang
read
ct
sampl
gener
influenza
viru
read
rang
read
differ
sensit
ct
threshold
p
fig
highest
ct
valu
influenza
viru
read
detect
sampl
read
influenza
viru
read
classifi
influenza
viru
obtain
sequenc
genexpert
assayneg
sampl
tabl
base
small
data
set
sensit
specif
ci
respect
strong
correl
ct
valu
read
per
sampl
classifi
influenza
viru
number
influenza
viru
read
per
million
read
fig
consensu
genom
sequenc
gener
minimum
depth
cover
influenza
viru
genom
sampl
anoth
two
gener
coverag
highest
ct
valu
sampl
influenza
viru
genom
sequenc
gener
fig
detect
control
viru
hazara
viru
genom
copiesml
highli
vari
demonstr
level
background
nontarget
rna
major
sourc
intersampl
variat
number
hazara
viru
read
per
sampl
rang
rpm
median
read
rpm
mean
read
rpm
tabl
four
sampl
gener
detect
hazara
viru
read
two
high
number
influenza
viru
read
sampl
ct
influenza
b
viru
read
sampl
ct
influenza
viru
read
act
dilut
control
signal
two
sampl
contain
detect
influenza
viru
read
sampl
ct
sampl
influenza
viru
neg
lack
control
detect
therefor
indic
loss
assay
sensit
due
high
level
background
nucleic
acid
present
sampl
select
subset
sampl
across
viral
titer
rang
resequenc
illumina
miseq
platform
proport
read
gener
map
influenza
viru
genom
similar
two
sequenc
technolog
fig
sampl
nearli
complet
genom
obtain
comparison
consensu
sequenc
deriv
nanopor
illumina
sequenc
show
concord
except
one
sampl
show
nucleotid
differ
ident
tabl
reconstruct
phylogeni
use
consensu
sequenc
ha
gene
fig
demonstr
close
relat
sequenc
expect
within
one
geograph
set
singl
influenza
season
within
clinic
sampl
sequenc
found
limit
evid
presenc
rna
virus
sampl
produc
read
map
human
coronaviru
addit
influenza
viru
read
suggest
coinfect
also
deriv
read
human
metapneumoviru
influenza
virusneg
sampl
provid
nearli
complet
genom
coverag
one
sampl
fig
sampl
detail
previous
final
use
sampl
collect
previou
anim
experi
test
reproduc
method
across
time
cours
model
influenza
viru
infect
three
ferret
swab
preinfect
day
sampl
day
follow
laboratori
infect
influenza
viru
proport
viral
read
present
time
point
highli
congruent
viral
titer
titer
shown
fig
sequenc
read
fig
gener
consensu
genom
sequenc
nanopor
data
day
postinfect
concord
illuminaderiv
consensu
sequenc
cdna
tabl
current
standard
assay
influenza
diagnosi
employ
within
larg
tertiari
referr
teach
hospit
studi
perform
genexpert
assay
cepheid
detect
influenza
b
virus
respiratori
syncyti
viru
rsv
wider
test
perform
subset
sampl
use
biofir
filmarray
respiratori
panel
target
common
respiratori
pathogen
virus
bacteria
assay
advantag
metagenom
approach
higher
sensit
shorter
handl
time
simpler
laboratori
workflow
rapid
time
result
min
respect
compar
metagenom
approach
limit
sequenc
data
inform
molecular
epidemiolog
drug
resist
type
gener
target
pathogen
assay
detect
small
number
pathogen
target
period
refin
assay
requir
event
newli
emerg
pathogen
divers
strain
establish
pathogen
lead
assay
escap
issu
affect
metagenom
sequenc
abil
detect
rna
virus
sequenceindepend
manner
time
undertak
laboratori
work
materi
cost
metagenom
sequenc
per
sampl
multiplex
six
sampl
per
flow
cell
purchas
flow
cell
togeth
cost
current
influenza
ab
rsv
genexpert
test
biofir
rp
panel
cost
per
sampl
exist
test
signific
advantag
short
handl
time
simpl
process
wherea
metagenom
sequenc
requir
h
skill
laboratori
staff
altern
approach
gener
sequenc
data
includ
ampliconbas
sequenc
influenza
viru
genom
howev
approach
detect
target
pathogen
requir
multipl
assay
complex
multiplex
primer
scheme
add
target
captur
divers
strain
origin
target
use
shortread
illumina
sequenc
instead
nanopor
sequenc
metagenom
sequenc
influenza
viru
provid
current
gold
standard
sequenc
qualiti
potenti
cost
save
per
base
sequenc
gener
howev
data
show
rel
modest
minimum
coverag
depth
nanoporegener
consensu
viral
genom
sequenc
ident
illumina
sequenc
sampl
compar
sampl
concord
base
differ
technolog
singl
sampl
appear
clear
case
genuin
disagr
long
shortread
approach
rather
simpli
due
higher
perbas
error
rate
nanopor
per
se
larger
divers
data
set
requir
set
rigor
threshold
base
call
current
wise
bear
potenti
issu
mind
compar
genom
sequenc
gener
differ
technolog
platform
perread
differ
base
accuraci
also
compens
increas
read
length
provid
confid
case
individu
read
taxonom
assign
consider
rel
cost
must
also
take
account
costsav
attribut
includ
substanti
lower
infrastructur
startup
cost
nanopor
sequenc
uniqu
abil
interrog
sequenc
data
gener
real
time
potenti
portabl
minion
devic
util
near
patient
potenti
decreas
turnaround
time
particularli
highvirusload
sampl
may
identifi
within
minut
throughput
nanopor
flow
cell
allow
small
number
sampl
run
immedi
rather
requir
sampl
batch
reach
number
suffici
cost
effici
run
greaterthroughput
shortread
sequenc
devic
futur
use
even
lowerthroughput
flow
cell
ont
flongl
adaptor
may
allow
individu
sampl
run
per
cell
offer
quicker
turnaround
per
sampl
minim
crosssampl
contamin
summari
tabl
compar
differ
approach
includ
supplement
materi
tabl
current
limit
metagenom
method
sensit
context
lowpathogentit
sampl
pcrbase
method
measur
absolut
count
viral
genom
copi
present
within
sampl
metagenom
sequenc
measur
proport
total
rna
viral
metagenom
sequenc
therefor
affect
level
nontarget
rna
within
given
sampl
wherea
pcr
demonstr
fig
tabl
detect
littl
genom
copi
per
ml
possibl
throat
swab
sampl
level
compar
pcrbase
method
variat
level
background
nucleic
acid
individu
sampl
make
detect
level
inconsist
develop
method
deplet
host
bacteri
rna
within
sampl
requir
improv
perform
assay
ct
valu
enrich
pathogen
sequenc
within
librari
either
target
captur
amplif
also
effect
method
reduc
limit
target
detect
requir
priori
knowledg
pathogen
target
full
rang
circul
viral
divers
target
method
discuss
albeit
increas
toler
divers
pcrbase
method
limit
compar
altern
sequenc
technolog
lack
confid
determin
presenc
minor
variant
due
limit
perread
accuraci
although
expect
address
futur
iter
ont
sequenc
summari
substanti
work
need
method
show
promis
gener
influenza
viru
sequenc
directli
respiratori
sampl
pathogenagnost
metagenom
sequenc
approach
offer
opportun
simultan
test
wide
rang
potenti
pathogen
provid
faster
rout
optimum
treatment
contribut
antimicrobi
stewardship
longer
term
approach
promis
routin
laboratori
test
provid
data
inform
treatment
vaccin
design
deploy
infect
control
polici
surveil
